Alaunos Therapeutics, INC 8-K filings

Alaunos Therapeutics has announced the resignation of its Vice President of Finance and the appointment of a new finance lead through a consulting agreement.

Alaunos Therapeutics has been notified by Nasdaq that it has regained compliance with the minimum $1.00 bid price requirement and will be subject to a mandatory panel monitor for one year.

Alaunos Therapeutics has completed a 1-for-15 reverse stock split, effective January 31, 2024, to consolidate its shares.

Alaunos Therapeutics will implement a 1-for-15 reverse stock split effective January 31, 2024, to maintain Nasdaq listing compliance.

Alaunos Therapeutics has appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer, effective January 20, 2024, while he continues to serve on the Board.